Clinical Research Directory
Browse clinical research sites, groups, and studies.
Zinc Sulphate in Treatment Fibrosis in HBV Patient Receiving Antiviral Therapy
Sponsor: Tanta University
Summary
This study aims to investigate the possible safety and efficacy of Zinc sulphate as antifibrotic agent in chronic HBV patient receiving antiviral therapy.
Official title: Clinical Study to Evaluate the Possible Antifibrotic Effect of Zinc Sulphate in Chronic HBV Patient Receiving Anti Viral Therapy
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
44
Start Date
2025-09-01
Completion Date
2026-09
Last Updated
2025-08-28
Healthy Volunteers
No
Conditions
Interventions
Entecavir (ETV)
Standard antiviral therapy with Entecavir 0.5 mg orally once daily for 6 months."(control group)
Zinc (zinc sulphate)
Zinc sulfate 220 mg orally once daily (50 mg elemental zinc) in addition to Entecavir 0.5 mg, for 6 months."